EssilorLuxottica maintains strong momentum, delivering a third consecutive quarter of double-digit top-line sales growth and outperforming consensus expectations. Smart glasses remain the key source of upside, with Ray-Ban Meta prescription lens penetration rising above 30%. Myopia management, Stellest's US rollout, and the acquisition of Top Charoen further expand EssilorLuxottica's addressable market, supporting a forecast double-digit sales CAGR and mid-teens EPS growth through 2028.